Keyphrases
Antipsychotics
83%
Schizophrenia
52%
Schizophrenic Patients
50%
Nave
38%
Patients with Schizophrenia
28%
Functional Magnetic Resonance Imaging
26%
Healthy Controls
22%
Ultra-high Risk for Psychosis
20%
Sensory Gating
20%
A1 Receptor
20%
Glucagon-like
20%
Receptor Agonist
20%
First-episode Psychosis
20%
Negative Symptoms
19%
Glucagon-like peptide-1 Receptor (GLP-1R)
14%
Negative Syndrome
14%
Ultra-high Risk
14%
Exenatide
12%
Hippocampus
11%
P50 Suppression
10%
Randomized Placebo-controlled Trial
10%
Electrophysiology
10%
Electroencephalography
10%
Amisulpride
10%
Positive Symptoms
10%
Non-diabetic
9%
Receptor Blockade
9%
Dopamine D2/3 Receptor
9%
Social Skills
9%
Prolactin
8%
Antipsychotic Monotherapy
8%
Neurocognition
8%
Hyperprolactinemia
8%
Brain Reward System
8%
Social Cognition
8%
Ventral Striatum
8%
Receptor Antagonist
8%
Gaussian Mixture Model
8%
Obese Patients
7%
Social Functioning
7%
Brief Assessment of Cognition in Schizophrenia
7%
Brain Volume
7%
Imputation Error
6%
Reject Option
6%
Data-driven Estimation
6%
Facial Emotion Recognition
6%
Attention Deficit Hyperactivity Disorder
6%
White Matter Volume
6%
Brain Stimulation Reward
6%
Resolved Method
6%
Neuroscience
Dementia Praecox
100%
Antipsychotic
89%
Functional Magnetic Resonance Imaging
24%
Sensory Gating
22%
Positive Syndrome
18%
Electroencephalography
17%
Negative Syndrome
15%
Glucagon-Like Peptide-1 Agonist
15%
Prolactin
13%
Eicosanoid Receptor
10%
Exenatide
10%
Amisulpride
10%
Receptor Antagonist
9%
Electrophysiology
9%
Hippocampus
8%
Reward System
8%
Meta-Analysis
8%
Electroencephalography
8%
Diabetes Mellitus
7%
Attention Deficit Hyperactivity Disorder
6%
Startle Response
6%
Prepulse Inhibition
6%
Default Mode Network
6%
Functional Connectivity
6%
Mismatch Negativity
6%
Glucagon-Like Peptide 1 Receptor
6%
Machine Learning Algorithm
5%
